Aster DM Quality Care Ltd Q4 FY2025 Concall Summary

Key Takeaways

• Margin story intact despite soft Q4: Operating EBITDA grew 30% to INR 806 crores for FY25, with margins expanding to 19.5% from 16.8%, even as Q4 revenue growth moderated to 2% YoY due to Ramadan and fewer days.
• Kerala cluster is the near-term drag: Occupancy worsened in Q4, driven by leadership change at flagship Medcity, Ramadan impact on local and international volumes, and a conscious pullback from low-paying Maldives business. Management calls it a short-term correction.
• Karnataka & Maharashtra is the star performer: Revenue grew 28% to INR 1,408 crores with EBITDA margin surging to 28.8%, powered by high-end treatments at Aster CMI and Aster Whitefield, which broke even in just three months.
• Merger with QCIL is the structural catalyst: The combined entity will be a top-three Indian hospital network with 38 hospitals and over 10,300 beds; INR 50-60 crores in identified synergies, with INR 20 crores already run-rate in Q4.
• What to watch next quarter: Whether Kerala occupancy bottoms and recovers as promised, the pace of synergy capture from QCIL procurement, and progress on the 2,100-bed organic expansion after acknowledged project delays of 3-4 months.

Kerala Cluster: The Quarter's Problem Child

• Occupancy worsened when it was expected to stabilize: The flagship Aster Medcity saw a leadership change with a new CEO and COO brought in, which management says caused a lack of focus on marketing and referral approach.
• Ramadan hit harder than anticipated: All of March fell within Ramadan, affecting local footfalls, elective cases, and medical value travel from Maldives and Oman. An extra calendar day in the prior year compounded the YoY comparison.
• Maldives business was deliberately shrunk: Management made a conscious decision to reduce Maldives volumes because they were not good paymasters; collections improved even though revenue dipped.
• IPD volumes declined 6%: The drop was driven by the medical tourism impact and the leadership challenge at the flagship unit.
• Strategy is to hold price, not chase volume: Management refuses to compete on discounts, positioning Aster as price and service leader in Kerala. 300 beds were added (200 in Kerala last quarter), which arithmetically depresses occupancy.
• Clinician base is stable: No major attrition at the clinician level; MIMS cluster benefits from legacy clinician ownership sentiment.
• Recovery is promised but unguided: Management expects a return to growth over the next couple of quarters and says the team is "now firing well," but declined to give occupancy guidance, offering only that high single-digit volume growth is expected going forward.

Alisha Moopen: "We remain confident in the long-term potential of the Kerala cluster and view this phase as a short-term correction with a broader trajectory of sustainable growth."

Karnataka & Maharashtra: The Margin Engine

• Cluster EBITDA margin hit 28.8% in FY25: Revenue grew 28% to INR 1,408 crores and operating EBITDA surged 48% to INR 321 crores, driven by high-end treatments at Aster CMI and Aster Whitefield.
• Aster Whitefield broke even in three months: In an established cluster like Bangalore, greenfield break-even can happen in a single quarter, versus 12-15 months for Aster RV and a typical 18 months in new geographic clusters.
• Sarjapur Road will add 430 beds: The fourth Bengaluru hospital targets the fastest-growing micro-market with ~35-40 lakh population and the highest affordability and insurance penetration due to software professionals. 300 beds expected by H2 FY27, the remaining 130 by FY29.
• Total Bengaluru capacity will exceed 2,000 beds: This reinforces Aster's position among the top three healthcare providers in the city.
• Mother and Child hospital expanding: 159 beds being added in Whitefield, contributing to FY26 revenue.

QCIL Merger: Synergies, Scale, and Structure

• INR 20 crores in procurement synergies already run-rate in Q4: The synergy wheel targets INR 50-60 crores in total EBITDA contribution, with other elements (repair and maintenance, food and beverage, medical value travel) still to kick in.
• QCIL delivered resilient growth despite headwinds: Revenue increased 12% YoY and EBITDA rose 14% in FY25, achieved while navigating political instability in Bangladesh, operational disruptions from revamping four hospitals, and merging three entities.
• Pricing adjustments provide a FY26 tailwind: Comparative pricing adjustments had only marginal impact in late Q4 but are expected to drive full-year benefit in FY26. Procurement strategies contributed additional realization in Q4 with full potential expected next year.
• Post-merger organizational structure is undecided: Management is still thinking through whether to run a cluster-based or different structure, calling it "really premature" to comment and asking for a few more quarters.
• Merger completion expected by Q4 FY26: Shareholders approved the preferential issuance, CCI granted approval, and the strategic share swap is complete. Final regulatory clearances from stock exchanges and NCLT remain.
• Combined entity will be a top-three Indian hospital network: 38 hospitals, over 10,300 beds across 27 cities.

Varun Khanna: "Our goal is to enhance service delivery, clinical outcomes, commercial operations, and digital transformation, and all of this while expanding our network."

Margin Trajectory: The 23-24% Ambition

• FY25 margin expansion was broad-based: Operating EBITDA margin reached 19.5%, up from 16.8%, driven by cost discipline, operational efficiencies, and the lab business turnaround from negative INR 9 crores to positive INR 10 crores EBITDA.
• Material cost has fallen 440 bps since FY20: Declined from 25.3% to 20.9% of revenue (excluding wholesale pharmacy) through disciplined procurement, centralized vendor negotiations, and optimized consumable usage.
• Manpower cost streamlined by ~70 bps: Achieved by enhancing span of control and reducing supervisory layers within key functional areas.
• Another 300-400 bps of margin improvement is targeted: Levers include material cost leverage (100 bps as volume doubles), further manpower cost reduction (1-1.2% per occupied bed per year), consolidation of functions, overhead consolidation (insurance, AMCs, non-medical consumables, electricity), and 30-32 MW captive power plants coming in H2.
• Q4 margin of 19.3% is called sustainable on a full-year basis: Management pointed to the consistent quarterly progression: 17%+ in Q1, over 21% in Q2, 19.3% in Q3 and Q4. Q2 is always the biggest quarter.
• 23-24% EBITDA margin target is for the combined entity with QCIL: The timeline is three to four years, and management says it is "very much committed."

Sunil Kumar: "We should be able to look at another 300 to 400 bps improvement in the margins."

Expansion: Beds, Delays, and Funding

• Over 2,100 beds in the organic pipeline: Includes Aster Kasargod (264 beds), Aster Capital Trivandrum (454 beds), Hyderabad Women and Children Hospital (300 beds), Sarjapur Road (430 beds), and brownfield expansions across existing facilities.
• Project delays of 3-4 months acknowledged: Brownfield expansions in Bangalore, Ongole, CMI, Medcity, and Hyderabad were delayed due to project challenges and a change in project lead. A new team is in place and management says past delays will not be repeated.
• Hyderabad Women and Children Hospital pushed to Q2 FY27: The warm shell required more infrastructure work than anticipated.
• Expansion is funded through internal accruals: INR 1,500 crores remains to be spent over the next three to four years; cash flow from operations at 78-80% should support the model without balance sheet pressure.
• QCIL expansion will use project debt: About 70% of project CapEx for QCIL's 1,200 new beds will be debt-funded at the entity level.
• Greenfield break-even is at 30% occupancy: Timing depends on brand recall and cluster approach: three months in established clusters like Bangalore, 12-15 months for Aster RV, and typically 18 months in new geographic clusters.

Sunil Kumar: "I want to highlight that this expansion will be funded through internal accruals and existing cash reserves without putting pressure on our balance sheet."

Other Clusters and Business Lines

• Andhra & Telangana cluster grew revenue 15%: EBITDA rose 45% to INR 60 crores, margin strengthened from 10% to 12.7%, and occupancy improved 460 bps to 54%. However, Q4 occupancy dipped from 55% to 51% due to one or two clinician departures in Guntur (cardiology and gynecology).
• Hyderabad cluster needed significant intervention: Two of five hospitals were underperforming. Actions taken: changed leadership teams, brought in a medical head, strengthened clinical recruitment, engaged external consultants on operating leakage, and renovated the Banjara facility which had been underinvested.
• Lab business turned around: Moved from negative EBITDA of INR 9 crores to positive INR 10 crores. Currently at 7-8% margin; the path to 20% requires increasing non-Aster business from 28% to 40-45% or near 50%. FY26 target is 36-38%.
• Wholesale pharmacy was deliberately shrunk: The B2B/trade supply segment was exited because logistics were not working and it was cash-loss-making. This artificially reduced overall growth from 4% to 2% but is expected to lead to profitable turnover starting Q1 FY26.
• Medical value travel is being diversified: New markets include African countries and Iraq; Oman continues to show traction; Maldives is approached cautiously due to payment pressure after a government change. Oncology is the focus for the African market.
• FY26 price increase of 3-3.5%: Applied across the payor mix.

Guidance & Commitments

Key Metrics